Daniel J Weisdorf
Overview
Explore the profile of Daniel J Weisdorf including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
381
Citations
17013
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Broman K, Meng Q, Holmqvist A, Balas N, Richman J, Landier W, et al.
JAMA Dermatol
. 2024 Dec;
PMID: 39693095
Importance: Cutaneous malignant neoplasms are the most common subsequent neoplasm after blood or marrow transplant (BMT), but a full assessment among survivors is lacking. Objective: To identify risk factors for...
2.
Balas N, Richman J, Landier W, Shrestha S, Bruxvoort K, Hageman L, et al.
Cancer
. 2024 Oct;
131(1):e35598.
PMID: 39380251
Background: The prevalence of suboptimal self-rated health (SRH) and its association with subsequent all-cause and cause-specific mortality after blood or marrow transplantation (BMT) were examined. Methods: Study participants were drawn...
3.
Bekadja M, Niederwiser D, Kharfan-Dabaja M, El Fakih R, Garderet L, Yakoub-Agha I, et al.
Bone Marrow Transplant
. 2024 Oct;
60(1):19-27.
PMID: 39375527
Autologous peripheral blood stem cell (PBSC) transplantation is a standard treatment of multiple myeloma (MM), Hodgkin lymphoma and various subtypes of non-Hodgkin lymphoma. Cryopreservation of hematopoietic stem cells is standard...
4.
Richard M, Yan C, Chen Y, Gibson C, Kalra R, Bosworth A, et al.
J Clin Oncol
. 2024 Aug;
42(31):3739-3750.
PMID: 39094067
Purpose: Therapy-related myeloid neoplasm (t-MN) is a life-threatening complication of autologous peripheral blood stem cell (PBSC) transplantation for non-Hodgkin lymphoma (NHL). Previous studies report an association between clonal hematopoiesis (CH)...
5.
Pidala J, Holtan S, Walton K, Kim J, Cao B, Elmariah H, et al.
Blood
. 2024 Jul;
144(22):2295-2307.
PMID: 39046783
Our phase 1 graft-versus-host disease (GVHD) prevention trial of JAK2 inhibitor, pacritinib (PAC; recommended phase 2 dose: 100 mg orally twice a day on day 0 to +70) plus sirolimus...
6.
Rashidi A, Ebadi M, Rehman T, Elhusseini H, Kazadi D, Halaweish H, et al.
Cancer Res Commun
. 2024 May;
4(6):1454-1466.
PMID: 38767452
Significance: Post-FMT expansion of Faecalibacterium, associated with donor microbiota engraftment, predicted a higher risk for aGVHD in alloHCT recipients. Although Faecalibacterium is a commensal genus with gut-protective and anti-inflammatory properties...
7.
Herzog S, Shanley R, Holtan S, MacMillan M, Weisdorf D, Jurdi N
Transplant Cell Ther
. 2024 May;
30(7):688.e1-688.e9.
PMID: 38734182
Post-transplantation cyclophosphamide (PTCy) following hematopoietic cell transplantation (HCT) has emerged as standard of care for graft-versus-host disease (GVHD) prevention in adult patients without increasing malignant relapse. We previously defined acute...
8.
Yan C, Richard M, Gibson C, He J, Bosworth A, Crossman D, et al.
J Clin Oncol
. 2024 Apr;
42(20):2415-2424.
PMID: 38635938
Purpose: Therapy-related myeloid neoplasm (t-MN) is a life-threatening complication of autologous peripheral blood stem cell transplantation (aPBSCT) for Hodgkin lymphoma (HL). Although previous studies have reported an association between clonal...
9.
Balas N, Richman J, Landier W, Shrestha S, Bruxvoort K, Hageman L, et al.
Leukemia
. 2024 Apr;
38(7):1592-1599.
PMID: 38580835
We examined the prevalence, risk factors, and association between pre-frailty and subsequent mortality after blood or marrow transplantation (BMT). Study participants were drawn from the BMT Survivor Study (BMTSS) and...
10.
Giri S, Harmon C, Landier W, Chen Y, Wu J, Hageman L, et al.
Cancer
. 2024 Apr;
130(15):2694-2702.
PMID: 38579107
Background: Autologous peripheral blood stem cell transplantation (aPBSCT) is the standard of care for adults with relapsed lymphoma, yet recipients remain at risk of developing chronic health conditions (CHCs). It...